Analysts Offer Predictions for STOK Q1 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Investment analysts at Wedbush issued their Q1 2026 EPS estimates for shares of Stoke Therapeutics in a research report issued to clients and investors on Tuesday, May 13th. Wedbush analyst L. Chico anticipates that the company will post earnings per share of ($0.64) for the quarter. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q2 2026 earnings at ($0.70) EPS, Q3 2026 earnings at ($0.73) EPS and Q4 2026 earnings at ($0.75) EPS.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million.

Several other equities research analysts have also recently weighed in on the stock. HC Wainwright dropped their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday. Chardan Capital reissued a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Cantor Fitzgerald raised shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Wednesday. Finally, Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Stoke Therapeutics has a consensus rating of “Buy” and a consensus target price of $23.20.

Stoke Therapeutics Stock Performance

STOK stock opened at $9.63 on Thursday. Stoke Therapeutics has a 52 week low of $5.35 and a 52 week high of $17.58. The firm’s fifty day moving average is $8.12 and its 200 day moving average is $9.99. The firm has a market cap of $525.77 million, a P/E ratio of -4.59 and a beta of 1.20.

Institutional Investors Weigh In On Stoke Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC lifted its position in shares of Stoke Therapeutics by 1,842.0% in the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock worth $36,000 after purchasing an additional 5,084 shares during the period. KLP Kapitalforvaltning AS purchased a new position in Stoke Therapeutics during the 4th quarter valued at about $63,000. Teacher Retirement System of Texas purchased a new position in Stoke Therapeutics during the 4th quarter valued at about $113,000. AlphaQuest LLC purchased a new position in Stoke Therapeutics during the 1st quarter valued at about $72,000. Finally, US Bancorp DE lifted its position in Stoke Therapeutics by 9,743.9% during the 1st quarter. US Bancorp DE now owns 11,222 shares of the company’s stock valued at $75,000 after acquiring an additional 11,108 shares during the period.

Insider Transactions at Stoke Therapeutics

In other news, insider Barry Ticho sold 3,884 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now directly owns 63,962 shares of the company’s stock, valued at approximately $554,550.54. This trade represents a 5.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the sale, the director now directly owns 148,253 shares of the company’s stock, valued at approximately $1,285,353.51. This represents a 6.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,532 shares of company stock valued at $143,332. Company insiders own 11.30% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.